Publications by authors named "Manojit M Swamynathan"

Patient genomics and mouse functional genetics have revealed that senescence is a barrier to metastatic progression of prostate cancer. Many efforts focus on eliminating senescent cells, whereas others aim to elucidate distinct characteristics that set them apart from normal and aging cells. Here, we discuss how exploration of the redox state of senescent cells could help define new markers and pro-oxidant vulnerabilities, drawing analogy to what is known about the redox sensitivity of proliferating cancer cells.

View Article and Find Full Text PDF

Prostate cancer (PCa) is one of the most common malignancies diagnosed among men and is the second leading cause of cancer-related death. Despite recent advancements in early diagnosis of PCa, androgen deprivation therapy (ADT) remains the most common treatment of PCa. Docetaxel (DTX) and Cabazitaxel (CTX) are two of the most extensively used drugs for metastatic castration-resistant prostate cancer (mCRPC).

View Article and Find Full Text PDF

Men taking antioxidant vitamin E supplements have increased prostate cancer (PC) risk. However, whether pro-oxidants protect from PC remained unclear. In this work, we show that a pro-oxidant vitamin K precursor [menadione sodium bisulfite (MSB)] suppresses PC progression in mice, killing cells through an oxidative cell death: MSB antagonizes the essential class III phosphatidylinositol (PI) 3-kinase VPS34-the regulator of endosome identity and sorting-through oxidation of key cysteines, pointing to a redox checkpoint in sorting.

View Article and Find Full Text PDF
Article Synopsis
  • Resistance to standard treatments for prostate cancer, like taxane and androgen deprivation therapy (ADT), leads to many deaths globally, prompting the development of a new genetically engineered mouse model called RapidCaP that mimics aggressive human prostate cancer.
  • Research identified FABP5 as a significant target by analyzing primary cancer cells from RapidCaP and patient datasets, showing that these mouse cells are resistant to conventional treatments but highly sensitive to a new small-molecule inhibitor, SBFI-103.
  • SBFI-103, which targets FABP5, is shown to be safe and effective at eliminating RapidCaP tumor cells in animal models, indicating its potential as a new treatment approach for difficult-to-treat prostate cancer.
View Article and Find Full Text PDF

Imaging defined aspects of functional tumor biology with bioluminescent reporter transgenes is a popular approach in preclinical drug development as it is sensitive, relatively high-throughput and low cost. However, the lack of internal controls subject functional bioluminescence to a number of unpredictable variables that reduce this powerful tool to semi-quantitative interpretation of large-scale effects. Here, we report the generation of sensitive and quantitative live reporters for two key measures of functional cancer biology and pharmacologic stress: the cell cycle and oxidative stress.

View Article and Find Full Text PDF

Purpose: Napabucasin (2-acetylfuro-1,4-naphthoquinone or BBI-608) is a small molecule currently being clinically evaluated in various cancer types. It has mostly been recognized for its ability to inhibit STAT3 signaling. However, based on its chemical structure, we hypothesized that napabucasin is a substrate for intracellular oxidoreductases and therefore may exert its anticancer effect through redox cycling, resulting in reactive oxygen species (ROS) production and cell death.

View Article and Find Full Text PDF
Article Synopsis
  • Metastatic prostate cancer typically shows bi-allelic mutations in key tumor suppressor genes, but often has large deletions of genes like PHLPP2 on chromosome 16q, which usually inhibits tumor growth.
  • In a study using a mutant mouse model, researchers discovered that losing PHLPP2 can surprisingly hinder prostate cancer progression while supporting Myc, a critical driver of aggressive cancer.
  • The researchers also found that inhibitors targeting PHLPP2 can effectively reduce Myc levels and eliminate mutant cancer cells, suggesting a potential treatment strategy by exploiting these frequent deletions as a therapeutic target.
View Article and Find Full Text PDF